Use of Dapagliflozin in Primary Prevention of Cardiotoxicity of Anthracycline Chemotherapy in Breast Cancer Patients (ALPACA)
Sponsor: Institute Of Oncology Ljubljana
Phase: 2
Disease: Breast cancer, Anthracycline-associated cardiotoxicity
EU trial number: 2026-525705-13-00
Population: Patients with breast cancer scheduled to receive anthracycline chemotherapy and undergoing primary prevention of treatment-related cardiac and vascular injury.
Register Investigator Interest
Interested in offering this trial to suitable patients?